IceCure Medical (ICCM) Expected to Post Quarterly Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect IceCure Medical to post earnings of ($0.83) per share and revenue of $0.88 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 18, 2026 at 10:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%. The business had revenue of $0.91 million during the quarter. On average, analysts expect IceCure Medical to post ($4.61) EPS for the current fiscal year and ($3.61) EPS for the next fiscal year.

IceCure Medical Stock Performance

ICCM opened at $0.79 on Wednesday. The company’s 50-day simple moving average is $1.44 and its two-hundred day simple moving average is $7.37. IceCure Medical has a 52-week low of $0.65 and a 52-week high of $22.50.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ICCM shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Thursday, October 15th. Zacks Research upgraded shares of IceCure Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, October 12th. Finally, Wall Street Zen downgraded shares of IceCure Medical from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, IceCure Medical has an average rating of “Hold” and a consensus target price of $30.00.

IceCure Medical Company Profile

IceCure Medical Ltd. is an Israel-based medical technology company focused on minimally invasive cryoablation treatments for cancerous and benign tumors. Its technology uses extremely cold temperatures, generated by liquid nitrogen, to destroy targeted tissue while limiting damage to surrounding areas. The company’s primary product is the ProSense Cryoablation System, which consists of a console, cryoprobes and related components. The system is designed to freeze and ablate tumors through a percutaneous procedure, generally under image guidance.